FindTrial
Sign In

Molecular targeted agent

3 trials

Sponsors

Kato Naoya, Ogasawara Sadahisa

Conditions

Hepatocellular carcinoma Chemotherapy

Phase 2

LAUNCH trial
Active, not recruitingJPRN-jRCTs031190017
Kato NaoyaHepatocellular carcinoma Chemotherapy
Start: 2020-06-26Target: 62Updated: 2026-06-29
REGAIN trial
Active, not recruitingJPRN-jRCTs031190103
Kato NaoyaHepatocellular carcinoma Chemotherapy
Start: 2020-01-14Target: 192Updated: 2026-06-29
R-evolution trial
Active, not recruitingJPRN-jRCTs031190236
Ogasawara SadahisaHepatocellular carcinoma Chemotherapy
Start: 2020-05-26Target: 30Updated: 2026-06-29

Related Papers

Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma
JHEP Reports2025-07-15
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
2024-06-06
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Clinical Cancer Research2023-10-0521 citations
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
Journal of Clinical Oncology2023-01-24